Kingsview Wealth Management LLC Grows Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Kingsview Wealth Management LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 12.4% in the 3rd quarter, Holdings Channel.com reports. The firm owned 4,430 shares of the medical instruments supplier’s stock after buying an additional 488 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Becton, Dickinson and were worth $987,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the stock. Mather Group LLC. grew its holdings in Becton, Dickinson and by 203.1% during the third quarter. Mather Group LLC. now owns 3,953 shares of the medical instruments supplier’s stock worth $881,000 after acquiring an additional 2,649 shares during the period. Meiji Yasuda Asset Management Co Ltd. grew its holdings in Becton, Dickinson and by 36.9% during the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 26,464 shares of the medical instruments supplier’s stock worth $5,897,000 after acquiring an additional 7,131 shares during the period. Meiji Yasuda Life Insurance Co grew its holdings in Becton, Dickinson and by 4.2% during the third quarter. Meiji Yasuda Life Insurance Co now owns 2,352 shares of the medical instruments supplier’s stock worth $524,000 after acquiring an additional 95 shares during the period. United Services Automobile Association grew its holdings in Becton, Dickinson and by 4.6% during the third quarter. United Services Automobile Association now owns 10,903 shares of the medical instruments supplier’s stock worth $2,430,000 after acquiring an additional 478 shares during the period. Finally, Wealthsource Partners LLC acquired a new position in Becton, Dickinson and during the third quarter worth $208,000. Hedge funds and other institutional investors own 87.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on BDX shares. Citigroup raised Becton, Dickinson and from a “sell” rating to a “neutral” rating and upped their target price for the company from $221.00 to $250.00 in a report on Monday, December 12th. Piper Sandler upped their target price on Becton, Dickinson and from $245.00 to $260.00 and gave the company a “neutral” rating in a report on Thursday, February 2nd. Morgan Stanley upped their target price on Becton, Dickinson and from $290.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, February 3rd. Cowen decreased their price objective on Becton, Dickinson and to $255.00 in a research note on Wednesday, November 16th. Finally, Evercore ISI decreased their price objective on Becton, Dickinson and to $270.00 in a research note on Wednesday, November 16th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $271.89.

Becton, Dickinson and Stock Performance

NYSE BDX opened at $232.89 on Wednesday. The business’s 50-day moving average price is $245.84 and its 200 day moving average price is $241.94. Becton, Dickinson and Company has a twelve month low of $215.90 and a twelve month high of $277.29. The company has a market capitalization of $66.12 billion, a PE ratio of 43.94, a price-to-earnings-growth ratio of 2.42 and a beta of 0.53. The company has a current ratio of 1.07, a quick ratio of 0.60 and a debt-to-equity ratio of 0.56.

Becton, Dickinson and (NYSE:BDX – Get Rating) last released its earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.98 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.30. Becton, Dickinson and had a return on equity of 13.52% and a net margin of 8.47%. The firm had revenue of $4.59 billion for the quarter, compared to the consensus estimate of $4.59 billion. During the same period in the prior year, the business posted $3.64 earnings per share. The firm’s revenue for the quarter was down 2.8% compared to the same quarter last year. On average, research analysts predict that Becton, Dickinson and Company will post 12.19 earnings per share for the current year.

Becton, Dickinson and Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 31st. Investors of record on Friday, March 10th will be given a dividend of $0.91 per share. The ex-dividend date of this dividend is Thursday, March 9th. This represents a $3.64 annualized dividend and a yield of 1.56%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 68.68%.

Insider Buying and Selling

In other news, EVP Richard Byrd sold 1,421 shares of the firm’s stock in a transaction dated Friday, February 3rd. The stock was sold at an average price of $248.60, for a total value of $353,260.60. Following the transaction, the executive vice president now directly owns 4,119 shares in the company, valued at approximately $1,023,983.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.31% of the stock is currently owned by company insiders.

Becton, Dickinson and Profile

(Get Rating)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.